- Home
- GLU vs ANVS Comparison
GLU vs ANVS Comparison
Compare GLU & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLU | ANVS |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 111.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLU | ANVS |
|---|---|---|
| Price | $19.90 | $3.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 12.4K | ★ 979.7K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $1.11 |
| 52 Week High | $15.40 | $5.60 |
Technical Indicators
Market Signals| Indicator | GLU | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 78.75 | 47.63 |
| Support Level | $18.36 | $3.46 |
| Resistance Level | $18.65 | $4.04 |
| Average True Range (ATR) | 0.25 | 0.35 |
| MACD | 0.15 | -0.13 |
| Stochastic Oscillator | 85.96 | 12.29 |
Price Performance
Historical ComparisonAbout GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.